These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 24767818

  • 1. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J, Cao J, Xu L, Zhou Y, Liu T, Li J, Hu Y.
    Bioorg Med Chem; 2014 Jun 01; 22(11):2955-65. PubMed ID: 24767818
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J, Han M, Ma X, Xu L, Cao J, Zhou Y, Li J, Liu T, Hu Y.
    Chem Biol Drug Des; 2014 Nov 01; 84(5):497-504. PubMed ID: 24751157
    [Abstract] [Full Text] [Related]

  • 3. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
    Li X, Hong D, Zhang M, Xu L, Zhou Y, Li J, Liu T.
    Eur J Med Chem; 2021 Oct 05; 221():113556. PubMed ID: 34087498
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q, Zhou T, Xi D, Li X, Lü Z, Xu F, Wang C, Niu Y, Xu P.
    Eur J Med Chem; 2020 Apr 15; 192():112160. PubMed ID: 32146375
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
    Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S.
    Bioorg Med Chem; 2014 Jun 15; 22(12):3091-5. PubMed ID: 24814885
    [Abstract] [Full Text] [Related]

  • 7. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y, Xu L, Zhang J, Zhang M, Lu J, He R, Xi J, Zhuang R, Li J, Zhou Y.
    Bioorg Med Chem; 2021 Jan 01; 29():115867. PubMed ID: 33223460
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J, Lei M, Wu W, Feng H, Wang J, Chen S, Zhu Y, Hu S, Liu Z, Jiang C.
    Bioorg Med Chem Lett; 2016 Apr 15; 26(8):1958-62. PubMed ID: 26965867
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W, Wang X, Zhang H, Wen T, Yang L, Miao H, Wang J, Liu H, Yang X, Lei M, Zhu Y.
    Bioorg Med Chem; 2021 Jun 15; 40():116182. PubMed ID: 33971487
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Cerchia C, Schirmeister T, Novellino E, Lavecchia A, Zappalà M, Grasso S.
    ChemMedChem; 2014 Aug 15; 9(8):1801-16. PubMed ID: 24891205
    [Abstract] [Full Text] [Related]

  • 14. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N, Sarraf D, Maréchal X, Janmamode N, Le Guével R, Genin E, Reboud-Ravaux M, Vidal J.
    Eur J Med Chem; 2018 Feb 10; 145():570-587. PubMed ID: 29339252
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
    Jorda R, Dušek J, Řezníčková E, Pauk K, Magar PP, Imramovský A, Kryštof V.
    Eur J Med Chem; 2017 Jul 28; 135():142-158. PubMed ID: 28441582
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
    Zhang J, Gao L, Xi J, Sheng L, Zhao Y, Xu L, Shao Y, Liu S, Zhuang R, Zhou Y, Li J.
    Bioorg Med Chem; 2016 Dec 01; 24(23):6206-6214. PubMed ID: 27765408
    [Abstract] [Full Text] [Related]

  • 17. Discovery of N-(2,3,5-triazoyl)mycophenolic amide and mycophenolic epoxyketone as novel inhibitors of human IMPDH.
    Sunohara K, Mitsuhashi S, Shigetomi K, Ubukata M.
    Bioorg Med Chem Lett; 2013 Sep 15; 23(18):5140-4. PubMed ID: 23937979
    [Abstract] [Full Text] [Related]

  • 18. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
    Marastoni M, Trapella C, Scotti A, Fantinati A, Ferretti V, Marzola E, Eleonora G, Gavioli R, Preti D.
    J Enzyme Inhib Med Chem; 2017 Dec 15; 32(1):865-877. PubMed ID: 28657369
    [Abstract] [Full Text] [Related]

  • 19. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A, Trapella C, Ferretti V, Gallerani E, Gavioli R, Marastoni M.
    J Enzyme Inhib Med Chem; 2016 Dec 15; 31(3):456-63. PubMed ID: 25942361
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D, Hallada LP, Le Chapelain C, Ganegamage SK, Dotson D, Rogelj S, Groll M, Tello-Aburto R.
    Eur J Med Chem; 2018 Sep 05; 157():962-977. PubMed ID: 30165344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.